Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00838955 |
Recruitment Status :
Terminated
(There was lack of enrollment since January 2013)
First Posted : February 9, 2009
Last Update Posted : September 16, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hodgkin's Lymphoma | Drug: Temsirolimus | Phase 2 |
Temsirolimus 25 mg IV infusion will be given once weekly on days 1, 8, 15 and 22 of each cycle. Patients will be assessed for response with CT scans after the second cycle, and then after every other cycle until disease progression is confirmed.
Patients will be treated with Temsirolimus until disease progression, or up to six cycles. Continuation of therapy beyond cycles is at the discretion of the investigator.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 14 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma |
Study Start Date : | January 2009 |
Actual Primary Completion Date : | October 2016 |
Actual Study Completion Date : | October 2017 |

Arm | Intervention/treatment |
---|---|
Experimental: Temsirolimus
Temsirolimus 25 mg IV infusion on Days 1, 8, 15, and 22 of a 28 day cycle
|
Drug: Temsirolimus
Temsirolimus 25 mg IV infusion on Days 1, 8, 15, and 22 of a 28 day cycle |
- To estimate the overall response rate (complete or partial response and stable disease by the IWG criteria) to temsirolimus [ Time Frame: 26 weeks ]To estimate the overall response rate (complete or partial response and stable disease by the IWG criteria) to temsirolimus
- To evaluate the toxicity of temsirolimus in this patient population. [ Time Frame: 26 weeks ]To evaluate the toxicity of temsirolimus in this patient population.
- To estimate the time to progression after treatment with temsirolimus. [ Time Frame: 5 years ]To estimate the time to progression after treatment with temsirolimus.
- To estimate overall survival after treatment with temsirolimus. [ Time Frame: 5 years ]To estimate overall survival after treatment with temsirolimus.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histologically confirmed classical Hodgkin Lymphoma or Lymphocyte Predominant Hodgkin Lymphoma with progressive disease during or at the end of the previous therapy, as defined by the IWG criteria.
- Patient must have nodular sclerosing, lymphocyte depleted, or mixed cellularity Hodgkin Lymphoma (Classical Hodgkin Lymphoma), or Lymphocyte predominant Hodgkin Lymphoma.
- Baseline measurements and evaluations must be obtained within 4 weeks of registration to the study.
- Abnormal PET scans will not constitute evaluable disease, unless verified by CT scan or other appropriate imaging.
- A clearly defined, bidimensionally measurable lymph node or tumor mass measuring at least 2 cm in diameter on a CT scan.
- Patient should have had at least one line of prior chemotherapy. Patients relapsing after treatment with radiation therapy alone are not eligible.
- Age > than or equal to 18 years.
- Both men and women and members of all races and ethnic groups are eligible for this trial.
- Women must not be pregnant or breast-feeding due to lack of information about the safety of administration of Temsirolimus in pregnant and lactating patients. All females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy.
- Women of childbearing potential and sexually active males are strongly advised to use an accepted and effective method of pregnancy prevention.
- Patient must have a SWOG performance status between 0-2.
- Patient must have no prior treatment with an m-TOR inhibitor.
- Patient must not have active infections at the time of registration.
- Laboratory studies should be obtained within two weeks of study registration except where noted otherwise. Allowable laboratory values are listed below:
- Absolute neutrophil count > than or equal 1,000/mm3
- Hemoglobin > than or equal 8 gm/dL
- Platelets > than or equal 75,000/mm3
- Serum creatinine < than or equal to two times the upper limit of normal. Creatinine should be measured within seven days of registration.
- Total serum bilirubin < than or equal to ≤ 1.5 times the upper limit of normal. Total bilirubin should be measured within seven days of registration.
- AST (SGOT) < than or equal to 3 times the upper limit of normal.
- ALT (SGPT) < than or equal to 3 times the upper limit of normal.
- Fasting total cholesterol < than or equal to 350 mg/dL.
- Fasting triglyceride level < than or equal to 400 mg/dL.
- Patient must have a life expectancy of three months.
Exclusion Criteria:
- Patient must not have received prior allogeneic stem cell transplantation. Prior autologous stem cell transplantation more than six months prior to registration is acceptable.
- Patient must not have received prior chemotherapy, biologic therapy or radiation within three weeks prior to registration, and should have recovered from toxicities of prior therapy (to Grade 0 or 1).
- Patient must not have evidence of active CNS disease.
- Patient must not have an uncontrolled comorbid disease, including hyperlipidemia, hypertriglyceridemia, diabetes mellitus, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia
- Patient must not have a psychiatric illness or social situation that would limit compliance with study requirements.
- Patient must have a life expectancy of three months.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00838955
United States, Illinois | |
Loyola Univeristy Medical Center, Cardinal Bernardin Cancer Center | |
Maywood, Illinois, United States, 60153 |
Principal Investigator: | Danielle Shafer, DO | Loyola University |
Responsible Party: | Kathleen Phelan, Assistant Professor, Loyola University |
ClinicalTrials.gov Identifier: | NCT00838955 |
Other Study ID Numbers: |
201170 |
First Posted: | February 9, 2009 Key Record Dates |
Last Update Posted: | September 16, 2020 |
Last Verified: | September 2020 |
Hodgkin's lymphoma relapsed Hodgkin's lymphoma refractory Hodgkin's lymphoma Temsirolimus |
Lymphoma Hodgkin Disease Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Sirolimus |
Anti-Bacterial Agents Anti-Infective Agents Antibiotics, Antineoplastic Antineoplastic Agents Antifungal Agents Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs |